Osteoarthritis (OA) is the most common of degenerative joint diseases. Relief of OA in the knee is being offered by Hyaluronan (HA) injections in the knee. HA's gelating properties reconstitute the buffer function of the synovial fluids. HA is degraded by the body, resulting in the need of repetitive multiple injections. CoreGel Biologics is developing RegenoGel™, a proprietary HA-fibrinogen conjugate with a significantly higher retention time than HA. RegenoGel™ is therefore expected to significantly reduce the injection frequency, thus adding to the patient's quality of life and reducing the need for medical attention. In this study the feasibility of the commercial development of RegenoGel™ is investigated.
